

PRESS RELEASE



Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

Conference call and webcast details:

Monday, November 13, 2023 @ 8:00am ET

Investor domestic dial-in: (800) 715-9871

Investor international dial-in: +1 (646) 307-1963

Conference ID: 3201224

Live webcast link: <https://ir.gracellbio.com/news-events/events-and-presentations>

A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-NHL and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on [LinkedIn](https://www.linkedin.com/company/gracellbio).

Media contacts Marvin Tang marvin.tang@gracellbio.com Jessica Laub jessica.laub@westwicke.com Investor contacts Gracie Tong gracie.tong@gracellbio.com Stephanie Carrington stephanie.carrington@westwicke.com